Last $27.13 USD
Change Today +0.33 / 1.23%
Volume 3.2M
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

nps pharmaceuticals inc (NPSP) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $39.68
52 Week Low
11/6/13 - $21.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

nps pharmaceuticals inc (NPSP) Related Businessweek News

View More BusinessWeek News

nps pharmaceuticals inc (NPSP) Details

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company also develops Natpara that is under Phase 3 clinical trial for the treatment of adult hypoparathyroidism; NPSP790 and NPSP795 calcilytic compounds, which are in Phase 1 clinical trial for application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria; and Teduglutide that is under preclinical stage for pediatric indications. It has collaborative agreements with GlaxoSmithKline to collaborate on the research, development, and commercialization of calcium receptor active compounds to treat osteoporosis and other bone metabolism disorders; and Kyowa Hakko Kirin Co. Ltd. to develop and commercialize compounds for the treatment of hyperparathyroidism. The company was founded in 1986 and is based in Bedminster, New Jersey.

207 Employees
Last Reported Date: 02/18/14
Founded in 1986

nps pharmaceuticals inc (NPSP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $413.7K
Senior Vice President and President of NPS Ph...
Total Annual Compensation: $395.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $407.9K
Vice President of Corporate Development & Str...
Total Annual Compensation: $223.1K
Compensation as of Fiscal Year 2013.

nps pharmaceuticals inc (NPSP) Key Developments

NPS Pharmaceuticals, Inc. - Special Call

NPS Pharmaceuticals, Inc. - Special Call

NPS Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reiterates Sales Guidance for the Year 2014

NPS Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $56,127,000 against $36,505,000 a year ago. Operating income was $5,790,000 compared with operating loss of $9,321,000 a year ago. Income before income tax expense was $2,255,000 against loss before income tax expense of $12,385,000 a year ago. Net income was $1,992,000 or $0.02 per basic and diluted share against net loss of $12,389,000 or $0.13 per basic and diluted share a year ago. For the six months, the company reported total revenues of $100,167,000 against $61,939,000 a year ago. Operating income was $2,842,000 compared with operating loss of $13,852,000 a year ago. Loss before income tax expense was $4,310,000 against $20,181,000 a year ago. Net loss was $4,584,000 or $0.04 per basic and diluted share against $20,185,000 or $0.22 per basic and diluted share a year ago. For the year 2014, the company is reiterating net sales guidance of $100 to $110 million.

NPS Pharmaceuticals, Inc. Initiates Phase 2A Study of NPSP795 in Adult Patients with Autosomal Dominant Hypocalcemia

NPS Pharmaceuticals, Inc. has initiated a Phase 2a study to evaluate the safety and tolerability of NPSP795 in adult patients with Autosomal Dominant Hypocalcemia (ADH), an ultra-rare genetic disorder of calcium homeostasis. ADH is caused by mutations of the calcium-sensing receptor (CaSR) gene that increase the sensitivity of the receptor to serum calcium. NPSP795 is a selective calcium receptor antagonist, which binds to the CaSR and decreases its sensitivity to serum calcium. It's mechanism of action is believed to restore the normal physiological action of the CaSR and address the underlying molecular defect in ADH to return to normal calcium homeostasis. The company expects to report preliminary top-line data from the study in late 2014 or early 2015. The non-randomized, open-label, dose-escalating study will evaluate the safety and tolerability of an intravenous (IV) infusion of NPSP795. The study will also test the ability of various doses of NPSP795 to stimulate parathyroid hormone secretion, increase blood calcium and decrease renal calcium excretion. The study is expected to enroll up to 12 patients at the National Institutes of Health's Clinical Center in Bethesda, MD.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPSP:US $27.13 USD +0.33

NPSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NPSP.
View Industry Companies

Industry Analysis


Industry Average

Valuation NPSP Industry Range
Price/Earnings 100.0x
Price/Sales 15.0x
Price/Book 22.4x
Price/Cash Flow 1,378.6x
TEV/Sales 13.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NPS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at